Trusted Resources: News & Meetings
Latest announcements and gatherings
Europe Grants Orphan Drug Status to JR-441, ERT for Sanfilippo A
The European Commission has granted an orphan drug designation to JR-441, JCR Pharmaceuticals’ brain-penetrating experimental enzyme replacement therapy (ERT) for Sanfilippo syndrome type A, the company has announced. The designation is given to investigative therapies with the potential to be safe and effective for rare, life-threatening, or chronically debilitating conditions that have no approved treatments, or where the potential therapy is showing significant benefit over existing treatments.
It is meant to accelerate JR-441’s clinical development and review by providing regulatory support and financial benefits. It also provides a 10-year marketing exclusivity period in Europe upon regulatory approval, if granted. JCR is planning to launch a global clinical trial testing the therapy in the first half of 2023. Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, is caused by the absence or reduced activity of the heparan N-sulfatase enzyme due to mutations in the SGSH gene.
BookmarkRelated Content
-
Enzyme Replacement Therapy With Galsulfase for Mucopolysaccharidosis Type VIMucopolysaccharidosis type VI (MPS VI) o...
-
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment o...Denali Therapeutics Inc., a biopharmaceu...
-
Beverly L. Davidson, PhDBeverly L. Davidson, PhD, is Director of...
-
Advances in Approaches to Care and Monitoring of MPS Diseasehttps://www.youtube.com/watch?v=JZSVzeiX...
-
Burden of Morbidity After Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor...Survival after blood or marrow transplan...
-
Elosulfase Alfa in the Treatment of Mucopolysaccharidosis Type IVA: Insights From the First Managed Access AgreementManaged access agreements provide a cruc...
-
Therapy-Type Related Long-Term Outcomes in Mucopolysaccaridosis Type II (Hunter Syndrome) – Case SeriesMucopolysaccharidosis type II (MPS II, H...
Powered by
